OTCQX:MRVFF - Post by User
Comment by
scroll4factson Apr 12, 2016 9:50pm
152 Views
Post# 24759820
RE:Forecast Q2 and 2016 P2 sales
RE:Forecast Q2 and 2016 P2 salesI suppose those strong sales numbers along with the positive results from the ankle sprain study put the new VP business development in the driver's seat for the ongoing partnering discussions in key ex-U.S. territories. He should be in a powerful negotiating position. I'm expecting this pharma to ink at least one important out-licensing agreement this year along with significant upfront payment. With its superior product attributes, I believe that P2 could become a global brand. Not much downside risk from here in my opinion.